Under the agreement, GE Healthcare will pay $9m in cash at closing for the assets of OMS, and up to an additional $5m in cash, subject to the achievement of certain agreed performance-based milestones.

GE Healthcare Nuclear Medicine general manager Nathan Hermony said that through the acquisition, they will expand investment in CZT technology to benefit molecular imaging customers, bringing new nuclear medicine technologies to healthcare professionals worldwide.

GE Healthcare’s Alcyone technology is a nuclear cardiology platform that combines CZT detectors, focused pin-hole collimation, 3D reconstruction and stationary data acquisition to reduce acquisition time and dose and improve overall image quality and workflow.

The Alcyone technology enables views of cardiac anatomy and functionality with greater clarity and speed, resulting in scan times as short as three minutes or up to a four- fold reduction in dose. It is available in SPECT (Discovery NM 530c) and SPECT/CT (Discovery NM/CT 570c) configurations.

The Alcyone technology helps clinicians provide patients with faster and more comfortable examinations and improve clinician confidence, eliminating equipment movement during the scan and reducing the risk of motion artifacts.